fda glp-1 warning letters november 2025 Pharmaceutical Advertising Regulations September 8, 2025: FDA launches

It mimics the GLP-1 hormone to stimulate insulin release, lower blood sugar levels, slow stomach emptying, and increase satiety, leading to reduced appetite and food intake

Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions

Researchers point to several reasons for this variation, including differences between specific GLP-1 medications, individual mental health history, the presence of eating disorders or mood disorders, and differences in dosage, duration of use, and overall health

Ninety minutes after drug administration, animals were transcardially perfused using 0.1 M PBS followed by 4% paraformaldehyde (PFA)

previously FDA-approved for type 2 diabetes and less commonly marketed in recent years